Risk factors for Gram-negative bacterial infections in febrile neutropenia

Haematologica

Volumn 90, Issue 8, 2005, Pages 1102-1109

  Cordonnier, Catherine ^a,g   Herbrecht, Raoul ^b   Buzyn, Agnès ^c   Leverger, Guy ^d   Leclercq, Roland ^e   Nitenberg, Gérard ^f   Bastuji Garin, Sylvie ^a  

^a FACULTÉ DE MÉDECINE   (France)

^b HÔPITAL DE HAUTEPIERRE   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d ARMAND TROUSSEAU HOSPITAL   (France)

^e CAEN UNIVERSITY HOSPITAL   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g HENRI MONDOR HOSPITAL   (France)

Author keywords

Febrile neutropenia; Gram negative infections; Prevalence rate; Risk factors

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CYTARABINE; NEOMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL INFECTION; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; INFECTION CONTROL; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; PREVALENCE; PROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; STEM CELL TRANSPLANTATION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; BACTEREMIA; FEVER; GRAM-NEGATIVE BACTERIAL INFECTIONS; HEMATOLOGIC DISEASES; HUMANS; MIDDLE AGED; NEUTROPENIA; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 24944529120     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationship between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40.
2. Cometta A, Zinner S, de Bock R, Calandra T, Gaya H, Klastersky J, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1995;39:445-52.
3. Cometta A, Calandra T, Gaya H, Calandra T, Gaya H, Klastersky J, et al. Monotherapy with meropenem versus combination therapy with ceftazidieme plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1996;40:1108-15.
4. Cordonnier C, Pico JL, Gardembas M, Gardembas M, Delmer A, Delain M, et al. Cefepime/amikacin versus cefatzidime amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. Clin Infect Dis 1997;24:41-51.
5. Glauser M, Boogaerts M, Cordonnier C. Empiric therapy of bacterial infections in severe neutropenia. Clin Microbiol Infect 1997;3 Suppl 1:S77-86.
6. Eking LS, Rubenstein EB, Rolston KVI, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997;25:247-59.
7. Hilf M, Yu VL, Sharp J, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989;87:540-6.
8. Collin BA, Leather HL, Wingard JR, Ramphal R. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis 2001;33:947-53.
9. Schimpf SC, Satterelee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971;284:1061-5.
10. Hughes WT, Armstrong DA, Bodey GP, Feld R, Mandell GL, Meyers JD, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161:381-96.
11. Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997;25:551-73.
12. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-51.
13. Struelens MJ. Multidisciplinary antimicrobial management teams: the way forward to control antimicrobial resistance in hospitals. Curr Opin Infect Dis 2003;16:305-7.
14. Livermore DM. Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis 2003 Suppl 1:S11-S23.
15. Jones R. Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia. Clin Infect Dis 1999;29:495-502.
16. Cordonnier C, Buzyn-Lévy A, Leverger G, Herbrecht R, Hunault M, Leclercq R, et al. Epidemiology and risk factors for Gram-positive Cocci infections in neutropenia: towards a more targeted antibiotic strategy. Club de Reflexion sur les Infections en Onco-Hematologie. Clin Infect Dis 2003;36:149-58.
17. Breslow NE, Day NA, eds. Statistical methods in cancer research. Vol I. The analysis of case-control studies. Lyon, France: International Agency for Research on Cancer, 1980. IARC scientific publication, no. 32.
18. Lemeshow S, Hosmer DW Jr. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 1982;115:92-106
19. Hanley J, McNeil B. The meaning and use of the area under a receiver operating characteristic ROC curve. Radiology 1982;143:29-36
20. Del Favero A, Menichetti F, Martino P, Bucaneve G, Micozzi A, Gentile G, et al. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Infection Program. Clin Infect Dis 2001;33:1295-301.
21. Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10:316-22.
22. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038-51.
23. Viscoli C, Bruzzi P, Castagnola E, Boni L, Calandra T, Gaya H, et al. Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Eur J Cancer 1994;30A:430-7.
24. Viscoli C, Paesmans M, Sanz M, Castagnola E, Klastersky J, Martino P, et al. Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer., Clin Infect Dis 2001;32:1532-7.
25. Amman RA, Hirt A, Luthy AR, Aebi C. Predicting bacteremia in children with fever and chemotherapy-induced neutropenia. Pediatr Infect Dis 2004;23:61-7.
26. Santolaya ME, Cofre J, Beresi V. C-reactive protein: a valuable aid for the management of febrile children with cancer and neutropenia. Clin Infect Dis 1994;18:589-95.
27. Engels EA, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998;16:1179-87.
28. Engel A, Steinbach G, Kern P, Kern WV. Diagnostic value of procalcitonin serum levels in neutropenic patients with fever: comparison with interleukin-8. Scand J Infect Dis 1999;31:185-9.
29. Fleischhack G, Cipic D, Juettner J, Hasan C, Bode U. Procalcitonin - a sensitive marker of febrile episodes in neutropenic children with cancer. Intens Care Med 2000;26:S202-11.
30. Kern WV, Heiss M, Steinbach G. Prediction of gram-negative bacteremia in patients with cancer and febrile neutropenia by means of interleukin-8 levels in serum: targeting empirical monotherapy versus combination therapy. Clin Infect Dis 2001;32:832-5.
31. Oude Nijhuis CS, Vellenga E, Daenen SM, van der Graaf WT, Gietema JA, Groen HJ, et al. Lipopolysaccharide-binding protein: a possible diagnosotic marker for Gram-negative bacteremia in neutropenic cancer patients. Intens Care Med 2003;29:2157-61.
32. Buzyn A, Tancrede C, Nitenberg G, Cordonnier C. Reflections on gut decontamination in hematology. Clin Microbiol Infect 1999;5:449-56.
33. Bochud PY, Calandra T, Francioli P. Bacteremia due to viridans streptococci in neutropenic patients: a review. Am J Med 1994;97:256-64.
34. Palmblad J, Lonnqvist B, Carlsson B, Grimfors G, Jarnmark M, Lerner R, et al. Oral ketoconazole prophylaxis for Candida infections during induction therapy for acute leukemia in adults: more bacteremias. J Intern Med 1992;231:363-70.
35. Schaffner A, Schaffner M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasia. J Infect Dis 1995;172:1035-41
36. Ramphal R. Is monotherapy for febrile neutropenia still a viable alternative? Clin Infect Dis 1999;29:508-14.
37. Calandra T, Glauser M. Immunocompromised animal models for the study of antibiotic combinations. Am J Med 1986;80:45-52.
38. De Jongh CA, Joshi JH, Newman KA, Moody MR, Wharton R, Standiford HC, et al. Antibiotic synergism and response in gram-negative bacteremia in granulocytopenic cancer patients. Am J Med 1986;80:96-100.
39. The EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of Gram negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 1987;317:1692-8.
40. Leibovici L, Paul M, Poznanski O, Drucker M, Samra Z, Konigsberger H, et al. Monotherapy versus beta-lactam aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997;41:1127-33.
41. Mol BW, Lijmer JG, Evers JLH, Bossuyt PMM. Characteristics of good diagnostic studies. Semin Reprod Med 2003;21:17-25.